Roche’s Genentech unit is laying off staff at its Bay Area headquarters for at least the third time this year, saying goodbye ...

AbbVie has scrapped an asset from its ongoing collaboration with Dragonfly Therapeutics, a spokesperson for the Chicago ...

Johnson & Johnson’s medical technology unit and its health data company Verily have penned separate new deals with technology ...

BridgeBio Pharma is having a banner week, with the Bay Area company’s encaleret acing a phase 3 trial just days after another ...

Secondary endpoints “indicate symptom reduction and patient benefit beyond improvement in disease activity,” according to ...

Kyverna saw an 8-point improvement on the MG-ADL scale, which measures the impact of gMG on daily functions, in the three ...

GSK once dreamed of harnessing the CD226 axis to create a new generation of blockbuster cancer drugs. | GSK once dreamed of ...

Cancer health tech company Flatiron Health has unveiled six new blood cancer data sets that together comprise information ...

Regeneron will be responsible for funding preclinical, clinical and commercial development for any ModeX product it chooses to advance from the research pact, with ModeX eligible for milestone ...

The deal is mainly focused on Incyte’s investigational mutant calreticulin selective monoclonal antibody treatment for the blood disorder essential thrombocythemia and the chronic bone marrow disorder ...

GSK’s antibody-drug conjugate strategy may be making more headlines recently, but the British pharma hasn’t forgotten about ...

Edesa Biotech has shared data from its truncated phase 3 respiratory failure trial, linking the anti-TLR4 antibody to ...